Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia

Bastit, Laurent; Vandebroek, A.; Altıntaş, Sevilay; Gaede, Bernd; Pintér, Tamás; Sütö, Tamás; Mossman, T.; E. Smith, Kay; F. Vansteenkiste, Johan

doi:10.1200/jco.2006.10.4620

Public

Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia

Published in Journal of Clinical Oncology • Mar 29, 2008

Authors:

Laurent Bastit

A. Vandebroek

Sevilay Altıntaş

Abstract

PURPOSE: The concomitant use of intravenous (IV) iron as a supplement to erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia is controversial. This study was designed to evaluate the efficacy and safety of darbepoetin alpha given with IV iron versus with local standard pra...

Subject

Darbepoetin alfa

Medicine

Anemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!